MIA Co-Medical Director opens SMR Congress in USA
21 November 2019
Professor Georgina Long, Co-Medical Director of Melanoma Institute Australia, has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
Professor Long is the first Australian and the first female President of SMR.
In her opening address, she summed up recent breakthroughs and advances in melanoma research and welcomed delegates from around the globe. This year's SMR Congress will cover a range of melanoma research and treatment related areas including the melanoma microenvironment, advances in early detection and prevention of melanoma, targeted and immunotherapies and advances in acral, mucosal and uveal melanoma. Women in STEM will also be a focus for the Congress.
Professor Long's opening address was followed by a Keynote Presentation on Cellular conversations that control cancer by University of California researcher, Professor Thea Tlsty, and the formal Welcome Reception. SMR continues into the weekend, with a packed program including a number of poster presentations from Melanoma Institute Australia researchers and students.
In sessions prior to the official opening, Co-Medical Director Professor Richard Scolyer led discussions at an International Melanoma Pathology Study Group workshop and the day-long International Melanoma Pathology Symposium.
The opening of SMR comes just a day after Professor Long and Professor Richard Scolyer were recognised as among the world’s most influential in their respective fields by being named in the prestigious Clarivate Analytics 2019 Highly Cited Researchers List.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.